Nuvectis Pharma
NVCT
31 hedge funds and large institutions have $7.15M invested in Nuvectis Pharma in 2024 Q4 according to their latest regulatory filings, with 7 funds opening new positions, 14 increasing their positions, 8 reducing their positions, and 7 closing their positions.
75% more repeat investments, than reductions
Existing positions increased: 14 | Existing positions reduced: 8
8% more capital invested
Capital invested by funds: $6.6M → $7.15M (+$546K)
1.21% more ownership
Funds ownership: 5.63% → 6.84% (+1.2%)
0% more funds holding
Funds holding: 31 → 31 (0)
0% more first-time investments, than exits
New positions opened: 7 | Existing positions closed: 7
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BWP
Baldwin Wealth Partners
Marion,
Massachusetts
|
+$1.14M |
| 2 |
Marshall Wace
London,
United Kingdom
|
+$512K |
| 3 |
OC
Oppenheimer & Co
New York
|
+$157K |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$151K |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$120K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
IAM
Iridian Asset Management
Westport,
Connecticut
|
-$348K |
| 2 |
Millennium Management
New York
|
-$243K |
| 3 |
Renaissance Technologies
New York
|
-$99.4K |
| 4 |
GCP
GSA Capital Partners
London,
United Kingdom
|
-$96.3K |
| 5 |
Citigroup
New York
|
-$55.9K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
RS
26
R Squared
Central,
Hong Kong
| $1.68K | +$1.94K | +310 | New |
|
27
JP Morgan Chase
New York
| $968 | -$81 | -13 | -7% |
|
28
BNP Paribas Financial Markets
Paris,
France
| $622 | +$720 | +115 | New |
|
|
SPIA
29
Steward Partners Investment Advisory
New York
| $541 | – | – | – |
|
|
PD
30
Point72 (DIFC)
Dubai,
United Arab Emirates
| $265 | +$307 | +49 | New |
|
|
NS
31
NBC Securities
Birmingham,
Alabama
| $27 | -$1.85K | -295 | -98% |
|
|
IAM
32
Iridian Asset Management
Westport,
Connecticut
| – | -$348K | -55,380 | Closed |
|
|
33
Renaissance Technologies
New York
| – | -$99.4K | -15,800 | Closed |
|
|
34
Citigroup
New York
| – | -$55.9K | -8,887 | Closed |
|
|
CFM
35
Catalyst Funds Management
Sydney NSW,
Australia
| – | -$5.66K | -900 | Closed |
|
|
TRCT
36
Tower Research Capital (TRC)
New York
| – | -$3.7K | -588 | Closed |
|
37
Fidelity Investments
Boston,
Massachusetts
| – | -$2.53K | -402 | Closed |
|
38
Nisa Investment Advisors
St. Louis,
Missouri
| – | -$75 | -12 | Closed |
|
NVCT Hedge Fund Activity: Q4 2024 in Review
31 of the 7,593 institutional investors tracked by Wall St. Rank reported a position in Nuvectis Pharma (NVCT) for Q4 2024, worth a combined $7.15M — up 8.3% from $6.6M a quarter earlier.
Fund positioning in NVCT was balanced in Q4 2024: 7 funds opened new positions, 7 closed out, 14 added to existing stakes and 8 trimmed.
The largest buyer was Baldwin Wealth Partners, adding an estimated $1.14M. The largest seller was Iridian Asset Management, exiting entirely with an estimated $348K sold.
- 31 institutional investors held Nuvectis Pharma (NVCT) as of Q4 2024, unchanged from Q3 2024.
- Funds reported $7.15M of Nuvectis Pharma stock for Q4 2024, up 8.3% quarter-over-quarter.
- 7 funds opened new Nuvectis Pharma positions in Q4 2024 and 7 closed out, a net change of 0 holders.
- The largest Nuvectis Pharma buyer in Q4 2024 was Baldwin Wealth Partners, an estimated $1.14M added.
- The largest Nuvectis Pharma seller in Q4 2024 was Iridian Asset Management, an estimated $348K sold.
Based on aggregated 13F filings for Q4 2024.